Moderna Q1 Revenue Triples to $389M, Beating Estimates; Stock Falls
Moderna reported Q1 2026 revenue of $389 million, more than tripling from $108 million a year ago and surpassing analyst expectations of $236.4 million. Despite the beat, the stock declined in after-hours trading.
Key Numbers
Moderna (MRNA) reported its first-quarter 2026 financial results, with revenue reaching $389 million, more than triple the $108 million recorded in the same period last year. The figure handily beat analyst consensus of $236.4 million.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $389M | $108M | +260% |
| Net Loss | $1.34B | N/A | - |
| EPS | -$3.40 | N/A | - |
Highlights from the Report
Moderna attributed the strong revenue growth to a surge in international COVID-19 vaccine sales, which offset a slowdown in domestic demand. The company noted that revenue exceeded its internal expectations.
Guidance
Moderna did not provide specific financial guidance for the next quarter but reiterated its focus on developing new vaccines and expanding its pipeline.
Stock Impact
Despite the revenue beat, Moderna's stock (MRNA) fell in after-hours trading. The decline reflects ongoing investor concerns about the sustainability of COVID-19 revenue as the pandemic recedes.
What This Means for Investors
Moderna's results demonstrate its ability to generate higher-than-expected COVID-19 vaccine revenue, but the significant net loss highlights profitability challenges. Investors should monitor the progress of the company's pipeline and its impact on future performance.
Frequently Asked Questions
Found this useful? Share it